m
Recent Posts
Connect with:
Tuesday / July 16.
HomemiproductsEikance 0.01%

Eikance 0.01%

Eikance 0.01%, the first pharmacotherapy registered on the Australian Register of Therapeutic Goods to slow the progression of myopia in children aged four to 14 years,1# may be initiated in children when myopia progresses ≥-1.0 D per year.

Eikance 0.01% single-use ampoules are sealed in foil pouches and are available in packs of 30 x 0.3 mL ampoules. The ophthalmic solution is sterile and preservative-free. Eikance 0.01% is a private, prescription only medicine available at community pharmacies across Australia.

To access product information and PBS status, turn to page 59.

Contact: Aspen Pharmacare Account Manager

References 

  1. Eikance Approved Product Information. # Australian Register of Therapeutic Goods. Accessed: 8 August 2021. Aspen Australia, St Leonards NSW 2065. Prepared: August 2022. AF 06771 ASP 2792.